| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Models, Statistical | 66 | 2022 | 5078 | 4.140 |
Why?
|
| Causality | 29 | 2024 | 1243 | 3.120 |
Why?
|
| Data Interpretation, Statistical | 33 | 2022 | 2691 | 2.690 |
Why?
|
| Epidemiologic Methods | 27 | 2013 | 1336 | 1.960 |
Why?
|
| Probability | 21 | 2012 | 2478 | 1.090 |
Why?
|
| Biometry | 13 | 2010 | 562 | 1.010 |
Why?
|
| Epidemiologic Research Design | 5 | 2017 | 368 | 1.010 |
Why?
|
| Randomized Controlled Trials as Topic | 23 | 2021 | 10203 | 0.980 |
Why?
|
| Estrogen Replacement Therapy | 4 | 2016 | 1208 | 0.920 |
Why?
|
| Research Design | 17 | 2023 | 6178 | 0.880 |
Why?
|
| Antiretroviral Therapy, Highly Active | 10 | 2015 | 1896 | 0.850 |
Why?
|
| Nose Neoplasms | 2 | 2023 | 249 | 0.840 |
Why?
|
| Cavernous Sinus | 1 | 2023 | 123 | 0.810 |
Why?
|
| Acquired Immunodeficiency Syndrome | 11 | 2011 | 2199 | 0.800 |
Why?
|
| Zidovudine | 7 | 2004 | 624 | 0.790 |
Why?
|
| Decompressive Craniectomy | 1 | 2020 | 76 | 0.670 |
Why?
|
| Epidemiologic Studies | 4 | 2010 | 674 | 0.670 |
Why?
|
| Braces | 1 | 2020 | 138 | 0.670 |
Why?
|
| Patient Dropouts | 3 | 2012 | 412 | 0.670 |
Why?
|
| CD4 Lymphocyte Count | 19 | 2019 | 2569 | 0.640 |
Why?
|
| Intention to Treat Analysis | 2 | 2017 | 414 | 0.640 |
Why?
|
| Selection Bias | 7 | 2015 | 359 | 0.620 |
Why?
|
| Anti-HIV Agents | 15 | 2019 | 4524 | 0.590 |
Why?
|
| Likelihood Functions | 5 | 2018 | 991 | 0.590 |
Why?
|
| Regression Analysis | 11 | 2018 | 6341 | 0.590 |
Why?
|
| Sphenoid Sinus | 1 | 2017 | 99 | 0.570 |
Why?
|
| Progestins | 2 | 2016 | 301 | 0.520 |
Why?
|
| Clinical Trials as Topic | 7 | 2012 | 7999 | 0.520 |
Why?
|
| Survival Analysis | 15 | 2020 | 10075 | 0.510 |
Why?
|
| Craniosynostoses | 1 | 2020 | 412 | 0.510 |
Why?
|
| Computer Graphics | 2 | 2007 | 340 | 0.500 |
Why?
|
| Cerebral Palsy | 1 | 2020 | 474 | 0.490 |
Why?
|
| Mortality | 4 | 2017 | 2898 | 0.490 |
Why?
|
| HIV Infections | 22 | 2019 | 17346 | 0.480 |
Why?
|
| Bayes Theorem | 8 | 2017 | 2329 | 0.480 |
Why?
|
| Air Pollution | 2 | 2022 | 2346 | 0.480 |
Why?
|
| Comparative Effectiveness Research | 3 | 2016 | 709 | 0.460 |
Why?
|
| Endoscopy | 4 | 2022 | 1851 | 0.460 |
Why?
|
| Observation | 4 | 2017 | 310 | 0.440 |
Why?
|
| Personnel, Hospital | 1 | 2015 | 285 | 0.430 |
Why?
|
| Pituitary Neoplasms | 2 | 2021 | 1324 | 0.420 |
Why?
|
| Disease Outbreaks | 5 | 2008 | 1762 | 0.400 |
Why?
|
| Viral Load | 10 | 2019 | 3330 | 0.400 |
Why?
|
| Clinical Protocols | 1 | 2017 | 1440 | 0.390 |
Why?
|
| Statistics as Topic | 12 | 2016 | 2358 | 0.370 |
Why?
|
| Adenoma | 2 | 2021 | 2159 | 0.370 |
Why?
|
| Vaccines | 3 | 2023 | 837 | 0.350 |
Why?
|
| Cross-Over Studies | 3 | 2022 | 2075 | 0.350 |
Why?
|
| Vietnam Conflict | 1 | 2010 | 100 | 0.340 |
Why?
|
| Humans | 151 | 2024 | 761326 | 0.340 |
Why?
|
| Treatment Refusal | 4 | 2006 | 429 | 0.330 |
Why?
|
| Computer Simulation | 13 | 2021 | 6236 | 0.330 |
Why?
|
| Heroin Dependence | 1 | 2010 | 172 | 0.330 |
Why?
|
| Longitudinal Studies | 17 | 2022 | 14597 | 0.330 |
Why?
|
| Communicable Diseases | 2 | 2008 | 880 | 0.330 |
Why?
|
| Weight Gain | 3 | 2020 | 2346 | 0.300 |
Why?
|
| HIV-1 | 9 | 2017 | 6860 | 0.300 |
Why?
|
| Anti-Retroviral Agents | 3 | 2015 | 1782 | 0.280 |
Why?
|
| Cholesterol, LDL | 1 | 2016 | 2381 | 0.270 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2012 | 1005 | 0.260 |
Why?
|
| RNA, Viral | 3 | 2019 | 2846 | 0.250 |
Why?
|
| Pneumonia, Pneumocystis | 2 | 2000 | 242 | 0.250 |
Why?
|
| Case-Control Studies | 12 | 2024 | 22124 | 0.250 |
Why?
|
| Linear Models | 3 | 2007 | 5871 | 0.220 |
Why?
|
| Cranial Fossa, Middle | 1 | 2023 | 29 | 0.220 |
Why?
|
| Benzoxazines | 2 | 2016 | 316 | 0.210 |
Why?
|
| Proportional Hazards Models | 12 | 2011 | 12450 | 0.210 |
Why?
|
| Stroke | 3 | 2020 | 9749 | 0.200 |
Why?
|
| Pharmacoepidemiology | 1 | 2006 | 350 | 0.200 |
Why?
|
| Biostatistics | 1 | 2024 | 164 | 0.200 |
Why?
|
| Epidemiology | 4 | 1989 | 279 | 0.200 |
Why?
|
| Mathematics | 8 | 2009 | 707 | 0.200 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2016 | 3244 | 0.200 |
Why?
|
| Drug Monitoring | 2 | 2019 | 961 | 0.200 |
Why?
|
| Particulate Matter | 1 | 2013 | 2587 | 0.190 |
Why?
|
| Risk | 12 | 1999 | 9605 | 0.190 |
Why?
|
| Decision Making | 4 | 2019 | 3929 | 0.190 |
Why?
|
| Citrus sinensis | 1 | 2020 | 14 | 0.180 |
Why?
|
| Dementia | 1 | 2015 | 2686 | 0.180 |
Why?
|
| Smoking Cessation | 3 | 2020 | 2056 | 0.180 |
Why?
|
| Stochastic Processes | 5 | 2008 | 356 | 0.180 |
Why?
|
| Pituitary Hormones | 1 | 2021 | 182 | 0.180 |
Why?
|
| Comorbidity | 5 | 2013 | 10498 | 0.180 |
Why?
|
| Rhizotomy | 1 | 2020 | 30 | 0.180 |
Why?
|
| Malus | 1 | 2020 | 50 | 0.170 |
Why?
|
| Environmental Exposure | 6 | 2004 | 4463 | 0.170 |
Why?
|
| Air Pollutants | 2 | 2013 | 2878 | 0.170 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2005 | 1164 | 0.170 |
Why?
|
| Frontal Bone | 1 | 2020 | 105 | 0.170 |
Why?
|
| Statistics, Nonparametric | 5 | 2006 | 2853 | 0.170 |
Why?
|
| Multicenter Studies as Topic | 4 | 2007 | 1703 | 0.170 |
Why?
|
| Visual Field Tests | 1 | 2022 | 411 | 0.170 |
Why?
|
| Seroepidemiologic Studies | 1 | 2021 | 397 | 0.170 |
Why?
|
| HIV Seropositivity | 2 | 2016 | 960 | 0.160 |
Why?
|
| Models, Theoretical | 5 | 2017 | 3577 | 0.160 |
Why?
|
| Craniotomy | 1 | 2023 | 741 | 0.160 |
Why?
|
| Quality of Life | 2 | 2020 | 13355 | 0.160 |
Why?
|
| Coronary Disease | 4 | 2016 | 5919 | 0.150 |
Why?
|
| Logistic Models | 6 | 2013 | 13251 | 0.150 |
Why?
|
| Models, Genetic | 3 | 2007 | 3445 | 0.150 |
Why?
|
| Female | 48 | 2024 | 392485 | 0.150 |
Why?
|
| Therapeutic Equivalency | 1 | 1998 | 134 | 0.150 |
Why?
|
| Educational Status | 1 | 2005 | 2520 | 0.150 |
Why?
|
| Patient Simulation | 1 | 2020 | 298 | 0.140 |
Why?
|
| Genetics | 1 | 1998 | 114 | 0.140 |
Why?
|
| Time Factors | 18 | 2018 | 39974 | 0.140 |
Why?
|
| Occupational Diseases | 7 | 1989 | 1491 | 0.140 |
Why?
|
| Breast Neoplasms | 7 | 2016 | 21009 | 0.140 |
Why?
|
| Treatment Outcome | 18 | 2020 | 64645 | 0.140 |
Why?
|
| Models, Biological | 4 | 2007 | 9468 | 0.140 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2000 | 662 | 0.140 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2018 | 188 | 0.140 |
Why?
|
| Orbit | 1 | 2020 | 457 | 0.140 |
Why?
|
| Linkage Disequilibrium | 1 | 2001 | 2004 | 0.140 |
Why?
|
| Medroxyprogesterone | 1 | 2016 | 35 | 0.140 |
Why?
|
| AIDS-Related Complex | 1 | 2016 | 107 | 0.140 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 6392 | 0.130 |
Why?
|
| Evaluation Studies as Topic | 2 | 2012 | 1626 | 0.130 |
Why?
|
| Cardiovascular Diseases | 5 | 2024 | 15499 | 0.130 |
Why?
|
| Neoplasm, Residual | 1 | 2021 | 1008 | 0.130 |
Why?
|
| Fibrinolytic Agents | 1 | 2005 | 2082 | 0.130 |
Why?
|
| Learning Curve | 1 | 2017 | 230 | 0.130 |
Why?
|
| Influenza, Human | 4 | 2010 | 1521 | 0.130 |
Why?
|
| Male | 46 | 2024 | 360621 | 0.130 |
Why?
|
| Drug Therapy, Combination | 5 | 2016 | 6309 | 0.120 |
Why?
|
| Drug Administration Schedule | 5 | 2012 | 4850 | 0.120 |
Why?
|
| Education, Nursing | 1 | 2015 | 80 | 0.120 |
Why?
|
| Visual Fields | 1 | 2022 | 1062 | 0.120 |
Why?
|
| Sarcoma, Kaposi | 1 | 1998 | 374 | 0.120 |
Why?
|
| Bone Transplantation | 1 | 2020 | 928 | 0.120 |
Why?
|
| Forced Expiratory Volume | 3 | 1992 | 1812 | 0.120 |
Why?
|
| Critical Illness | 1 | 2007 | 2722 | 0.120 |
Why?
|
| Algorithms | 9 | 2010 | 14025 | 0.120 |
Why?
|
| Nonlinear Dynamics | 1 | 1997 | 493 | 0.120 |
Why?
|
| Bariatric Surgery | 1 | 2024 | 991 | 0.120 |
Why?
|
| Ecology | 1 | 1994 | 105 | 0.110 |
Why?
|
| United States | 17 | 2024 | 72317 | 0.110 |
Why?
|
| Chromosome Mapping | 1 | 2001 | 4638 | 0.110 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2016 | 621 | 0.110 |
Why?
|
| Thrombophlebitis | 1 | 1993 | 289 | 0.110 |
Why?
|
| Middle Aged | 33 | 2024 | 220774 | 0.100 |
Why?
|
| Risk Factors | 20 | 2020 | 74152 | 0.100 |
Why?
|
| Neurosurgical Procedures | 1 | 2023 | 2071 | 0.100 |
Why?
|
| Brain Ischemia | 1 | 2005 | 3048 | 0.100 |
Why?
|
| Dermoid Cyst | 1 | 2013 | 92 | 0.100 |
Why?
|
| Health Status | 1 | 2005 | 4075 | 0.100 |
Why?
|
| Cohort Studies | 13 | 2016 | 41440 | 0.100 |
Why?
|
| Developed Countries | 4 | 2017 | 449 | 0.100 |
Why?
|
| Adult | 38 | 2024 | 221122 | 0.100 |
Why?
|
| Life Style | 3 | 2020 | 3915 | 0.100 |
Why?
|
| Hospital Mortality | 1 | 2005 | 5291 | 0.100 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2012 | 212 | 0.100 |
Why?
|
| Confidence Intervals | 3 | 2010 | 2927 | 0.100 |
Why?
|
| Tumor Burden | 1 | 2017 | 1887 | 0.100 |
Why?
|
| Job Satisfaction | 1 | 2015 | 544 | 0.100 |
Why?
|
| Cause of Death | 6 | 2017 | 3685 | 0.100 |
Why?
|
| Europe | 5 | 2017 | 3420 | 0.090 |
Why?
|
| Sample Size | 2 | 2021 | 839 | 0.090 |
Why?
|
| Nevirapine | 1 | 2012 | 273 | 0.090 |
Why?
|
| Hydrocephalus | 1 | 2018 | 764 | 0.090 |
Why?
|
| Postmenopause | 2 | 2016 | 2513 | 0.090 |
Why?
|
| Cognition Disorders | 1 | 2005 | 3979 | 0.090 |
Why?
|
| Military Personnel | 1 | 2020 | 1246 | 0.090 |
Why?
|
| Exercise | 5 | 2020 | 5883 | 0.090 |
Why?
|
| Forecasting | 1 | 2020 | 2928 | 0.090 |
Why?
|
| Oseltamivir | 1 | 2010 | 75 | 0.090 |
Why?
|
| Fishes | 1 | 2013 | 603 | 0.090 |
Why?
|
| Scalp | 1 | 2013 | 389 | 0.090 |
Why?
|
| Family Characteristics | 2 | 2012 | 1003 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2002 | 4371 | 0.080 |
Why?
|
| Patient Compliance | 2 | 2017 | 2690 | 0.080 |
Why?
|
| Mathematical Computing | 2 | 2007 | 142 | 0.080 |
Why?
|
| Smoking | 11 | 2013 | 9051 | 0.080 |
Why?
|
| Nose | 1 | 2013 | 521 | 0.080 |
Why?
|
| Obesity | 3 | 2018 | 12934 | 0.080 |
Why?
|
| Adolescent | 7 | 2023 | 88305 | 0.080 |
Why?
|
| Emergency Medical Services | 1 | 2020 | 1922 | 0.080 |
Why?
|
| Epistasis, Genetic | 1 | 2010 | 352 | 0.080 |
Why?
|
| Propensity Score | 1 | 2016 | 1908 | 0.080 |
Why?
|
| Mass Screening | 1 | 2004 | 5428 | 0.070 |
Why?
|
| Incidence | 5 | 2021 | 21336 | 0.070 |
Why?
|
| Data Collection | 3 | 2001 | 3324 | 0.070 |
Why?
|
| Random Allocation | 6 | 1990 | 2389 | 0.070 |
Why?
|
| Postoperative Complications | 2 | 2021 | 15647 | 0.070 |
Why?
|
| Sensitivity and Specificity | 5 | 2004 | 14665 | 0.070 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2008 | 276 | 0.070 |
Why?
|
| Population Density | 1 | 2007 | 193 | 0.070 |
Why?
|
| Chicago | 1 | 2007 | 254 | 0.070 |
Why?
|
| Temperature | 1 | 2013 | 2229 | 0.070 |
Why?
|
| Life Expectancy | 2 | 1991 | 1242 | 0.070 |
Why?
|
| Mining | 1 | 1987 | 93 | 0.070 |
Why?
|
| Weight Loss | 2 | 2016 | 2683 | 0.070 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2010 | 445 | 0.070 |
Why?
|
| Odds Ratio | 5 | 2010 | 9639 | 0.070 |
Why?
|
| Heparin | 1 | 1993 | 1633 | 0.070 |
Why?
|
| Disease | 2 | 2004 | 672 | 0.070 |
Why?
|
| Disease Transmission, Infectious | 2 | 2010 | 559 | 0.070 |
Why?
|
| Feeding Behavior | 2 | 2020 | 3187 | 0.060 |
Why?
|
| Urban Population | 1 | 2013 | 2033 | 0.060 |
Why?
|
| Genetic Markers | 1 | 2012 | 2612 | 0.060 |
Why?
|
| Estrogens | 2 | 2010 | 1521 | 0.060 |
Why?
|
| Analysis of Variance | 4 | 2004 | 6231 | 0.060 |
Why?
|
| Survival Rate | 4 | 2013 | 12710 | 0.060 |
Why?
|
| Diet | 3 | 2018 | 8074 | 0.060 |
Why?
|
| Follow-Up Studies | 9 | 2021 | 39108 | 0.060 |
Why?
|
| Bulimia | 1 | 2007 | 400 | 0.060 |
Why?
|
| Body Mass Index | 3 | 2016 | 12949 | 0.060 |
Why?
|
| Prospective Studies | 11 | 2017 | 54405 | 0.060 |
Why?
|
| Reproducibility of Results | 4 | 2012 | 20092 | 0.060 |
Why?
|
| Double-Blind Method | 4 | 2010 | 12329 | 0.060 |
Why?
|
| Environment | 1 | 2010 | 1122 | 0.060 |
Why?
|
| Monte Carlo Method | 3 | 2017 | 1257 | 0.060 |
Why?
|
| History, 20th Century | 2 | 2010 | 2770 | 0.060 |
Why?
|
| Child Development | 2 | 2006 | 2304 | 0.060 |
Why?
|
| Cyanates | 1 | 1983 | 20 | 0.060 |
Why?
|
| Toluene 2,4-Diisocyanate | 1 | 1983 | 10 | 0.060 |
Why?
|
| Length of Stay | 1 | 2017 | 6422 | 0.060 |
Why?
|
| Markov Chains | 2 | 2017 | 965 | 0.060 |
Why?
|
| Alkynes | 2 | 2016 | 320 | 0.060 |
Why?
|
| Didanosine | 1 | 2003 | 151 | 0.060 |
Why?
|
| Veterans | 2 | 2024 | 2647 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2001 | 2642 | 0.050 |
Why?
|
| Germany | 1 | 2005 | 875 | 0.050 |
Why?
|
| Child | 4 | 2020 | 80156 | 0.050 |
Why?
|
| Homosexuality, Male | 2 | 2004 | 1334 | 0.050 |
Why?
|
| Child, Preschool | 5 | 2020 | 42251 | 0.050 |
Why?
|
| Cyclopropanes | 2 | 2016 | 432 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 9275 | 0.050 |
Why?
|
| Motor Skills | 1 | 2006 | 520 | 0.050 |
Why?
|
| Nervous System | 1 | 2006 | 545 | 0.050 |
Why?
|
| Research Subjects | 1 | 2004 | 249 | 0.050 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2003 | 137 | 0.050 |
Why?
|
| Hormone Replacement Therapy | 2 | 2013 | 751 | 0.050 |
Why?
|
| Infant | 4 | 2020 | 36202 | 0.050 |
Why?
|
| Premature Birth | 1 | 2014 | 1782 | 0.050 |
Why?
|
| Atrial Fibrillation | 1 | 2020 | 5127 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 3889 | 0.050 |
Why?
|
| Myocardial Infarction | 3 | 2005 | 11454 | 0.050 |
Why?
|
| Air Pollutants, Occupational | 3 | 1989 | 407 | 0.050 |
Why?
|
| Pentamidine | 1 | 2000 | 44 | 0.050 |
Why?
|
| Public Health Practice | 1 | 2003 | 219 | 0.050 |
Why?
|
| Hypertension | 2 | 1998 | 8539 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2007 | 1791 | 0.040 |
Why?
|
| Risk Assessment | 4 | 2017 | 23981 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2016 | 7954 | 0.040 |
Why?
|
| Carbon Compounds, Inorganic | 2 | 1989 | 12 | 0.040 |
Why?
|
| Silicon Compounds | 2 | 1989 | 16 | 0.040 |
Why?
|
| Heart | 1 | 1993 | 4405 | 0.040 |
Why?
|
| Aged | 13 | 2021 | 169179 | 0.040 |
Why?
|
| Pituitary Gland | 1 | 2022 | 635 | 0.040 |
Why?
|
| Silicon | 2 | 1989 | 142 | 0.040 |
Why?
|
| Risperidone | 1 | 2001 | 381 | 0.040 |
Why?
|
| Penetrance | 1 | 2000 | 388 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2000 | 17872 | 0.040 |
Why?
|
| Boston | 2 | 2007 | 9333 | 0.040 |
Why?
|
| Graft vs Leukemia Effect | 1 | 1999 | 121 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 1998 | 5820 | 0.040 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2006 | 1351 | 0.040 |
Why?
|
| Health Surveys | 1 | 2008 | 4059 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2010 | 2176 | 0.040 |
Why?
|
| Time | 1 | 2020 | 545 | 0.040 |
Why?
|
| Prenatal Care | 1 | 2006 | 1139 | 0.040 |
Why?
|
| Infant, Newborn | 4 | 2014 | 26211 | 0.040 |
Why?
|
| Isoniazid | 1 | 1999 | 283 | 0.040 |
Why?
|
| Eye | 1 | 2022 | 710 | 0.040 |
Why?
|
| Models, Structural | 1 | 1998 | 341 | 0.040 |
Why?
|
| Aerosols | 1 | 2000 | 635 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2010 | 3057 | 0.040 |
Why?
|
| Public Health | 1 | 1991 | 2667 | 0.040 |
Why?
|
| Vitamins | 1 | 2006 | 1635 | 0.040 |
Why?
|
| Disease Progression | 4 | 2011 | 13500 | 0.040 |
Why?
|
| Developmental Disabilities | 1 | 2006 | 1508 | 0.030 |
Why?
|
| Retrospective Studies | 5 | 2021 | 80575 | 0.030 |
Why?
|
| Proteins | 1 | 2012 | 6034 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2004 | 2712 | 0.030 |
Why?
|
| Homozygote | 1 | 2001 | 1796 | 0.030 |
Why?
|
| Systems Analysis | 1 | 2017 | 169 | 0.030 |
Why?
|
| Pregnancy | 4 | 2014 | 29858 | 0.030 |
Why?
|
| Family | 1 | 2007 | 3197 | 0.030 |
Why?
|
| Respiration Disorders | 2 | 1989 | 367 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2004 | 1780 | 0.030 |
Why?
|
| Bisexuality | 1 | 1998 | 294 | 0.030 |
Why?
|
| Carbon | 2 | 1989 | 665 | 0.030 |
Why?
|
| Research | 1 | 2004 | 1977 | 0.030 |
Why?
|
| Influenza in Birds | 2 | 2006 | 76 | 0.030 |
Why?
|
| Prognosis | 3 | 2021 | 29588 | 0.030 |
Why?
|
| Birds | 2 | 2006 | 168 | 0.030 |
Why?
|
| Neuropsychological Tests | 2 | 2006 | 7045 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2018 | 578 | 0.030 |
Why?
|
| Exostoses | 1 | 1975 | 30 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2006 | 6815 | 0.030 |
Why?
|
| Zimbabwe | 1 | 2015 | 135 | 0.030 |
Why?
|
| Methotrexate | 1 | 2002 | 1720 | 0.030 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 2 | 2006 | 113 | 0.030 |
Why?
|
| Age Factors | 2 | 2018 | 18401 | 0.030 |
Why?
|
| Heterozygote | 1 | 2001 | 2803 | 0.030 |
Why?
|
| Prevalence | 2 | 2008 | 15719 | 0.030 |
Why?
|
| Massachusetts | 2 | 2016 | 8837 | 0.030 |
Why?
|
| HIV Protease Inhibitors | 1 | 2016 | 432 | 0.030 |
Why?
|
| Spondylitis, Ankylosing | 1 | 1975 | 152 | 0.030 |
Why?
|
| Benchmarking | 1 | 2020 | 1045 | 0.030 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2006 | 2152 | 0.030 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1999 | 710 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2000 | 3639 | 0.030 |
Why?
|
| Antidepressive Agents | 1 | 2005 | 2897 | 0.030 |
Why?
|
| Developing Countries | 1 | 2006 | 2887 | 0.030 |
Why?
|
| Phenotype | 2 | 2001 | 16603 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2000 | 984 | 0.030 |
Why?
|
| Mammography | 1 | 2004 | 2429 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2006 | 3413 | 0.030 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1997 | 549 | 0.030 |
Why?
|
| Antirheumatic Agents | 1 | 2002 | 1371 | 0.030 |
Why?
|
| Birth Weight | 2 | 1999 | 2100 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 1993 | 680 | 0.020 |
Why?
|
| Mental Disorders | 1 | 2012 | 6839 | 0.020 |
Why?
|
| El Salvador | 1 | 1991 | 33 | 0.020 |
Why?
|
| Endometrial Neoplasms | 1 | 2001 | 1365 | 0.020 |
Why?
|
| Lung Neoplasms | 3 | 1998 | 13333 | 0.020 |
Why?
|
| Tanzania | 2 | 2006 | 1387 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 1999 | 2693 | 0.020 |
Why?
|
| Toxoplasmosis | 1 | 1991 | 94 | 0.020 |
Why?
|
| Wisconsin | 1 | 2010 | 122 | 0.020 |
Why?
|
| Uganda | 1 | 2015 | 1332 | 0.020 |
Why?
|
| Bipolar Disorder | 1 | 2007 | 5091 | 0.020 |
Why?
|
| Young Adult | 4 | 2021 | 59196 | 0.020 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2010 | 155 | 0.020 |
Why?
|
| Registries | 1 | 2005 | 8223 | 0.020 |
Why?
|
| Alleles | 1 | 2000 | 6909 | 0.020 |
Why?
|
| Sulfur Dioxide | 1 | 1989 | 178 | 0.020 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 1988 | 39 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 1999 | 4286 | 0.020 |
Why?
|
| Asbestos | 1 | 1991 | 251 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 1 | 1997 | 1051 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 1993 | 2217 | 0.020 |
Why?
|
| Rwanda | 1 | 2011 | 665 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 1993 | 1376 | 0.020 |
Why?
|
| Alcohol Drinking | 2 | 2013 | 4027 | 0.020 |
Why?
|
| Sampling Studies | 1 | 1989 | 615 | 0.020 |
Why?
|
| Chemoprevention | 1 | 2010 | 326 | 0.020 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 58946 | 0.020 |
Why?
|
| Accidents, Home | 1 | 1988 | 71 | 0.020 |
Why?
|
| Depressive Disorder | 1 | 2000 | 3728 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 1504 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 1992 | 771 | 0.020 |
Why?
|
| Silicosis | 1 | 1986 | 47 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2024 | 12144 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2002 | 3760 | 0.020 |
Why?
|
| Eating | 1 | 2013 | 1537 | 0.020 |
Why?
|
| Containment of Biohazards | 1 | 2006 | 37 | 0.020 |
Why?
|
| Antipsychotic Agents | 2 | 2015 | 3067 | 0.020 |
Why?
|
| Psychotic Disorders | 1 | 2001 | 3223 | 0.020 |
Why?
|
| Depression | 1 | 2005 | 8122 | 0.020 |
Why?
|
| Animals | 5 | 2013 | 168388 | 0.020 |
Why?
|
| Ethics, Medical | 1 | 1991 | 783 | 0.020 |
Why?
|
| Health Promotion | 1 | 2017 | 2213 | 0.020 |
Why?
|
| Family Health | 1 | 2010 | 1257 | 0.020 |
Why?
|
| Maximal Expiratory Flow Rate | 1 | 1984 | 42 | 0.020 |
Why?
|
| Accidents, Traffic | 1 | 1991 | 816 | 0.020 |
Why?
|
| Forced Expiratory Flow Rates | 1 | 1984 | 74 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2020 | 4813 | 0.010 |
Why?
|
| Respiratory Function Tests | 2 | 1986 | 1682 | 0.010 |
Why?
|
| Overweight | 1 | 2016 | 2412 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 10764 | 0.010 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 1996 | 2508 | 0.010 |
Why?
|
| Maximum Allowable Concentration | 1 | 1983 | 63 | 0.010 |
Why?
|
| Genotype | 1 | 1998 | 12982 | 0.010 |
Why?
|
| Hong Kong | 1 | 2003 | 166 | 0.010 |
Why?
|
| Multivariate Analysis | 2 | 1996 | 12059 | 0.010 |
Why?
|
| Morbidity | 1 | 1988 | 1750 | 0.010 |
Why?
|
| Patient Isolation | 1 | 2003 | 100 | 0.010 |
Why?
|
| Communicable Disease Control | 2 | 2004 | 849 | 0.010 |
Why?
|
| Singapore | 1 | 2003 | 291 | 0.010 |
Why?
|
| Cities | 1 | 2004 | 546 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2015 | 8632 | 0.010 |
Why?
|
| Spirometry | 1 | 1984 | 928 | 0.010 |
Why?
|
| Longevity | 1 | 1988 | 1065 | 0.010 |
Why?
|
| Quarantine | 1 | 2003 | 181 | 0.010 |
Why?
|
| Contact Tracing | 1 | 2003 | 271 | 0.010 |
Why?
|
| Lead Poisoning | 1 | 1983 | 322 | 0.010 |
Why?
|
| Malaria | 1 | 1990 | 1227 | 0.010 |
Why?
|
| Disaster Planning | 1 | 2006 | 557 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 6473 | 0.010 |
Why?
|
| Lung | 2 | 1989 | 9994 | 0.010 |
Why?
|
| Tuberculosis | 1 | 2011 | 2016 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1985 | 1265 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 2006 | 1879 | 0.010 |
Why?
|
| Health Behavior | 1 | 2009 | 2641 | 0.010 |
Why?
|
| Lead | 1 | 1983 | 879 | 0.010 |
Why?
|
| Physicians | 1 | 2015 | 4591 | 0.010 |
Why?
|
| Placebos | 1 | 2001 | 1667 | 0.010 |
Why?
|
| Burns | 1 | 1988 | 1864 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 5841 | 0.010 |
Why?
|
| Heel | 1 | 1975 | 37 | 0.010 |
Why?
|
| Elbow | 1 | 1975 | 130 | 0.010 |
Why?
|
| Health Policy | 1 | 2006 | 2684 | 0.010 |
Why?
|
| Wrist | 1 | 1975 | 227 | 0.010 |
Why?
|
| RNA | 1 | 2003 | 2723 | 0.010 |
Why?
|
| Knee | 1 | 1975 | 280 | 0.010 |
Why?
|
| Humerus | 1 | 1975 | 272 | 0.010 |
Why?
|
| Pelvic Bones | 1 | 1975 | 270 | 0.010 |
Why?
|
| Forearm | 1 | 1975 | 427 | 0.010 |
Why?
|
| Infant, Low Birth Weight | 1 | 1996 | 869 | 0.010 |
Why?
|
| Occupations | 2 | 1984 | 515 | 0.010 |
Why?
|
| Foot | 1 | 1975 | 575 | 0.010 |
Why?
|
| Leukemia | 1 | 1999 | 1523 | 0.010 |
Why?
|
| Thoracic Vertebrae | 1 | 1975 | 596 | 0.010 |
Why?
|
| Leg | 1 | 1975 | 1089 | 0.010 |
Why?
|
| Hand | 1 | 1975 | 902 | 0.010 |
Why?
|
| Aging | 2 | 1986 | 8704 | 0.010 |
Why?
|
| Age of Onset | 1 | 1996 | 3303 | 0.010 |
Why?
|
| Cervical Vertebrae | 1 | 1975 | 981 | 0.000 |
Why?
|
| Syndrome | 1 | 1975 | 3268 | 0.000 |
Why?
|
| Femur | 1 | 1975 | 1308 | 0.000 |
Why?
|
| Immunization Schedule | 1 | 1990 | 227 | 0.000 |
Why?
|
| Immunization, Secondary | 1 | 1990 | 368 | 0.000 |
Why?
|
| Vital Capacity | 1 | 1989 | 970 | 0.000 |
Why?
|
| Dust | 1 | 1989 | 487 | 0.000 |
Why?
|
| National Health Programs | 1 | 1990 | 440 | 0.000 |
Why?
|
| Brazil | 1 | 1990 | 1230 | 0.000 |
Why?
|
| Lumbar Vertebrae | 1 | 1975 | 1879 | 0.000 |
Why?
|
| Radiography | 1 | 1975 | 6966 | 0.000 |
Why?
|
| Immunity | 1 | 1990 | 997 | 0.000 |
Why?
|
| Employment | 1 | 1989 | 1118 | 0.000 |
Why?
|
| Connecticut | 1 | 1983 | 364 | 0.000 |
Why?
|
| Edetic Acid | 1 | 1983 | 283 | 0.000 |
Why?
|
| Blood Cell Count | 1 | 1983 | 397 | 0.000 |
Why?
|
| Hematocrit | 1 | 1983 | 625 | 0.000 |
Why?
|
| Program Evaluation | 1 | 1990 | 2494 | 0.000 |
Why?
|
| Hemolysis | 1 | 1983 | 424 | 0.000 |
Why?
|
| Anemia | 1 | 1983 | 1508 | 0.000 |
Why?
|
| Chronic Disease | 1 | 1983 | 9319 | 0.000 |
Why?
|
| Cross-Sectional Studies | 1 | 1986 | 26108 | 0.000 |
Why?
|
| Neoplasms | 1 | 1985 | 22158 | 0.000 |
Why?
|